DA与DEA、DHA三种化疗方案诱导治疗急性髓系白血病的疗效比较

目的探讨柔红霉素+阿糖胞苷(DA)、柔红霉素+依托泊苷+阿糖胞苷(DEA)、柔红霉素+高三尖杉酯碱+阿糖胞苷(DHA)三种不同化疗方案诱导治疗急性髓系白血病(AML)的疗效性和不良反应。方法将1999年2月至2010年6月广元市中心医院血液科收治的122例初治AML患者随机分为三组,分别接受DA(40例)、DEA(40例)、DHA(42例)方案化疗,比较三组的完全缓解(CR)率、总体反应(RR)率和不良反应发生情况。结果 DA组CR率为50.0%,DEA组为75.0%,DHA组为73.8%,三组临床疗效比较差异有统计学意义(P<0.05)。三组均未出现相关并发症死亡的现象,三组不良反应比较差异无统计学意义(P>0.05)。结论 DEA和DHA方案与DA方案相比,治疗初治AML患者的疗效较好。

Effect Comparison of DA, DEA and DHA Chemotherapy for Acute Mydoid Leukemia

Objective To compare the effectiveness and side effects of three chemotherapy regimens dannorubicin ＋ eytarabine （DA） and daunorubicin ＋ etoposide ＋ cytarabine （ DEA ） and dannorubicin ＋ homoharringtanine ＋ cytarabine （ DHA ） ] in patients with acute myeloid leukemia （AML）. Methods 122 newly diagnosed AML patients from Guangyuan City Central Hospital during Feb. 1999 and Jun. 2010 were randomized into DA （ 40 cases ）, DEA （ 40 cases ） and DHA （ 42 cases ） group. Complete remission rate （CR） ,response rate （RR）, and side effect of the three groups were compared. Results CR rate of DA group was 50.0% ,of DEA group was 75%, of DHA group was 73.8%, the difference was statistically significant（P 〈 0.05 ）. No complications or death happened in all groups, and the adverse reactions of the three groups were not significantly different （P 〉 0.05 ）. Conclusion DEA and DHA chemotherapy have better therapeutic effect than DA for newly diagnosed AML patients.